A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine-refractory, differentiated thyroid cancer: A clinical outcomes and biomarker assessment.
Identifieur interne : 002503 ( Ncbi/Merge ); précédent : 002502; suivant : 002504A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine-refractory, differentiated thyroid cancer: A clinical outcomes and biomarker assessment.
Auteurs : Maria E. Cabanillas [États-Unis] ; Martin Schlumberger [France] ; Barbara Jarzab [Pologne] ; Renato G. Martins [États-Unis] ; Furio Pacini [Italie] ; Bruce Robinson [Australie] ; Judith C. Mccaffrey [États-Unis] ; Manisha H. Shah [États-Unis] ; Donald L. Bodenner [États-Unis] ; Duncan Topliss [Australie] ; Corina Andresen [États-Unis] ; James P. O'Brien [États-Unis] ; Min Ren [États-Unis] ; Yasuhiro Funahashi [États-Unis] ; Roger Allison [Australie] ; Rossella Elisei [Italie] ; Kate Newbold [Royaume-Uni] ; Lisa F. Licitra [Italie] ; Steven I. Sherman [États-Unis] ; Douglas W. Ball [États-Unis]Source :
- Cancer [ 1097-0142 ] ; 2015.
Descripteurs français
- KwdFr :
- Adulte, Adulte d'âge moyen, Antinéoplasiques (usage thérapeutique), Femelle, Humains, Inhibiteurs de protéines kinases (effets indésirables), Inhibiteurs de protéines kinases (usage thérapeutique), Marqueurs biologiques tumoraux (analyse), Mâle, Phénylurées (effets indésirables), Phénylurées (usage thérapeutique), Quinoléines (effets indésirables), Quinoléines (usage thérapeutique), Radio-isotopes de l'iode (effets indésirables), Radio-isotopes de l'iode (usage thérapeutique), Résultat thérapeutique, Sujet âgé, Tumeurs de la thyroïde (mortalité), Tumeurs de la thyroïde (traitement médicamenteux), Évolution de la maladie.
- MESH :
- analyse : Marqueurs biologiques tumoraux.
- effets indésirables : Inhibiteurs de protéines kinases, Phénylurées, Quinoléines, Radio-isotopes de l'iode.
- mortalité : Tumeurs de la thyroïde.
- traitement médicamenteux : Tumeurs de la thyroïde.
- usage thérapeutique : Antinéoplasiques, Inhibiteurs de protéines kinases, Phénylurées, Quinoléines, Radio-isotopes de l'iode.
- Adulte, Adulte d'âge moyen, Femelle, Humains, Mâle, Résultat thérapeutique, Sujet âgé, Évolution de la maladie.
English descriptors
- KwdEn :
- Adult, Aged, Antineoplastic Agents (therapeutic use), Biomarkers, Tumor (analysis), Disease Progression, Female, Humans, Iodine Radioisotopes (adverse effects), Iodine Radioisotopes (therapeutic use), Male, Middle Aged, Phenylurea Compounds (adverse effects), Phenylurea Compounds (therapeutic use), Protein Kinase Inhibitors (adverse effects), Protein Kinase Inhibitors (therapeutic use), Quinolines (adverse effects), Quinolines (therapeutic use), Thyroid Neoplasms (drug therapy), Thyroid Neoplasms (mortality), Treatment Outcome.
- MESH :
- chemical , adverse effects : Iodine Radioisotopes, Phenylurea Compounds, Protein Kinase Inhibitors, Quinolines.
- chemical , analysis : Biomarkers, Tumor.
- chemical , therapeutic use : Antineoplastic Agents, Iodine Radioisotopes, Phenylurea Compounds, Protein Kinase Inhibitors, Quinolines.
- drug therapy : Thyroid Neoplasms.
- mortality : Thyroid Neoplasms.
- Adult, Aged, Disease Progression, Female, Humans, Male, Middle Aged, Treatment Outcome.
Abstract
Lenvatinib is an oral, multitargeted tyrosine kinase inhibitor of the vascular endothelial growth factor receptors 1 through 3 (VEGFR1-VEGFR3), fibroblast growth factor receptors 1 through 4 (FGFR1-FGFR4), platelet-derived growth factor receptor α (PDGFRα), ret proto-oncogene (RET), and v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog (KIT) signaling networks implicated in tumor angiogenesis. Positive phase 1 results in solid tumors prompted a phase 2 trial in patients with advanced, radioiodine-refractory, differentiated thyroid cancer (RR-DTC).
DOI: 10.1002/cncr.29395
PubMed: 25913680
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 002A75
- to stream PubMed, to step Curation: 002A05
- to stream PubMed, to step Checkpoint: 002A05
Links to Exploration step
pubmed:25913680Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine-refractory, differentiated thyroid cancer: A clinical outcomes and biomarker assessment.</title><author><name sortKey="Cabanillas, Maria E" sort="Cabanillas, Maria E" uniqKey="Cabanillas M" first="Maria E" last="Cabanillas">Maria E. Cabanillas</name><affiliation wicri:level="2"><nlm:affiliation>Department of Endocrine Neoplasia and Hormonal Disorders, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Texas</region></placeName><wicri:cityArea>Department of Endocrine Neoplasia and Hormonal Disorders, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston</wicri:cityArea></affiliation></author><author><name sortKey="Schlumberger, Martin" sort="Schlumberger, Martin" uniqKey="Schlumberger M" first="Martin" last="Schlumberger">Martin Schlumberger</name><affiliation wicri:level="4"><nlm:affiliation>Department of Nuclear Medicine and Endocrine Oncology, Gustave Roussy Institute and Université Paris-Sud, Villejuif, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Nuclear Medicine and Endocrine Oncology, Gustave Roussy Institute and Université Paris-Sud, Villejuif</wicri:regionArea><wicri:noRegion>Villejuif</wicri:noRegion><orgName type="university">Université Paris-Sud</orgName><placeName><settlement type="city">Orsay</settlement><region type="region" nuts="2">Île-de-France</region></placeName></affiliation></author><author><name sortKey="Jarzab, Barbara" sort="Jarzab, Barbara" uniqKey="Jarzab B" first="Barbara" last="Jarzab">Barbara Jarzab</name><affiliation wicri:level="1"><nlm:affiliation>Department of Nuclear Medicine and Endocrine Oncology, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice Branch, Gliwice Poland, Wybrzeze Armii Krajowej 15, 44-101 Gliwice, Poland.</nlm:affiliation><country xml:lang="fr">Pologne</country><wicri:regionArea>Department of Nuclear Medicine and Endocrine Oncology, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice Branch, Gliwice Poland, Wybrzeze Armii Krajowej 15, 44-101 Gliwice</wicri:regionArea><wicri:noRegion>44-101 Gliwice</wicri:noRegion></affiliation></author><author><name sortKey="Martins, Renato G" sort="Martins, Renato G" uniqKey="Martins R" first="Renato G" last="Martins">Renato G. Martins</name><affiliation wicri:level="2"><nlm:affiliation>Department of Thoracic/Head and Neck Oncology, School of Medicine, University of Washington, Seattle, Washington.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Washington (État)</region></placeName><wicri:cityArea>Department of Thoracic/Head and Neck Oncology, School of Medicine, University of Washington, Seattle</wicri:cityArea></affiliation></author><author><name sortKey="Pacini, Furio" sort="Pacini, Furio" uniqKey="Pacini F" first="Furio" last="Pacini">Furio Pacini</name><affiliation wicri:level="1"><nlm:affiliation>Section of Endocrinology, University of Siena, Siena, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Section of Endocrinology, University of Siena, Siena</wicri:regionArea><wicri:noRegion>Siena</wicri:noRegion></affiliation></author><author><name sortKey="Robinson, Bruce" sort="Robinson, Bruce" uniqKey="Robinson B" first="Bruce" last="Robinson">Bruce Robinson</name><affiliation wicri:level="4"><nlm:affiliation>Faculty of Medicine, Cancer Genetics Unit, Kolling Institute, Royal North Shore Hospital, University of Sydney, New South Wales, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Faculty of Medicine, Cancer Genetics Unit, Kolling Institute, Royal North Shore Hospital, University of Sydney, New South Wales</wicri:regionArea><orgName type="university">Université de Sydney</orgName><placeName><settlement type="city">Sydney</settlement><region type="état">Nouvelle-Galles du Sud</region></placeName></affiliation></author><author><name sortKey="Mccaffrey, Judith C" sort="Mccaffrey, Judith C" uniqKey="Mccaffrey J" first="Judith C" last="Mccaffrey">Judith C. Mccaffrey</name><affiliation wicri:level="2"><nlm:affiliation>H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Floride</region></placeName><wicri:cityArea>H. Lee Moffitt Cancer Center and Research Institute, Tampa</wicri:cityArea></affiliation></author><author><name sortKey="Shah, Manisha H" sort="Shah, Manisha H" uniqKey="Shah M" first="Manisha H" last="Shah">Manisha H. Shah</name><affiliation wicri:level="2"><nlm:affiliation>Ohio State University Comprehensive Cancer Center, Columbus, Ohio.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Ohio</region></placeName><wicri:cityArea>Ohio State University Comprehensive Cancer Center, Columbus</wicri:cityArea></affiliation></author><author><name sortKey="Bodenner, Donald L" sort="Bodenner, Donald L" uniqKey="Bodenner D" first="Donald L" last="Bodenner">Donald L. Bodenner</name><affiliation wicri:level="2"><nlm:affiliation>Department of Geriatrics, University of Arkansas for Medical sciences, Little Rock, Arkansas.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Arkansas</region></placeName><wicri:cityArea>Department of Geriatrics, University of Arkansas for Medical sciences, Little Rock</wicri:cityArea></affiliation></author><author><name sortKey="Topliss, Duncan" sort="Topliss, Duncan" uniqKey="Topliss D" first="Duncan" last="Topliss">Duncan Topliss</name><affiliation wicri:level="1"><nlm:affiliation>Department of Endocrinology and Diabetes, The Alfred Hospital, Melbourne, Victoria, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Department of Endocrinology and Diabetes, The Alfred Hospital, Melbourne, Victoria</wicri:regionArea><wicri:noRegion>Victoria</wicri:noRegion></affiliation></author><author><name sortKey="Andresen, Corina" sort="Andresen, Corina" uniqKey="Andresen C" first="Corina" last="Andresen">Corina Andresen</name><affiliation wicri:level="2"><nlm:affiliation>Eisai Inc, Woodcliff Lake, New Jersey.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">New Jersey</region></placeName><wicri:cityArea>Eisai Inc, Woodcliff Lake</wicri:cityArea></affiliation></author><author><name sortKey="O Brien, James P" sort="O Brien, James P" uniqKey="O Brien J" first="James P" last="O'Brien">James P. O'Brien</name><affiliation wicri:level="2"><nlm:affiliation>Eisai Inc, Woodcliff Lake, New Jersey.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">New Jersey</region></placeName><wicri:cityArea>Eisai Inc, Woodcliff Lake</wicri:cityArea></affiliation></author><author><name sortKey="Ren, Min" sort="Ren, Min" uniqKey="Ren M" first="Min" last="Ren">Min Ren</name><affiliation wicri:level="2"><nlm:affiliation>Eisai Inc, Woodcliff Lake, New Jersey.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">New Jersey</region></placeName><wicri:cityArea>Eisai Inc, Woodcliff Lake</wicri:cityArea></affiliation></author><author><name sortKey="Funahashi, Yasuhiro" sort="Funahashi, Yasuhiro" uniqKey="Funahashi Y" first="Yasuhiro" last="Funahashi">Yasuhiro Funahashi</name><affiliation wicri:level="2"><nlm:affiliation>Eisai Inc, Andover, Massachusetts.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Massachusetts</region></placeName><wicri:cityArea>Eisai Inc, Andover</wicri:cityArea></affiliation></author><author><name sortKey="Allison, Roger" sort="Allison, Roger" uniqKey="Allison R" first="Roger" last="Allison">Roger Allison</name><affiliation wicri:level="1"><nlm:affiliation>Cancer Care Services, The Royal Brisbane and Women's Hospital, Herston, Queensland, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Cancer Care Services, The Royal Brisbane and Women's Hospital, Herston, Queensland</wicri:regionArea><wicri:noRegion>Queensland</wicri:noRegion></affiliation></author><author><name sortKey="Elisei, Rossella" sort="Elisei, Rossella" uniqKey="Elisei R" first="Rossella" last="Elisei">Rossella Elisei</name><affiliation wicri:level="4"><nlm:affiliation>Department of Endocrinology, University of Pisa, Pisa, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Endocrinology, University of Pisa, Pisa</wicri:regionArea><placeName><settlement type="city">Pise</settlement><region nuts="2">Toscane</region><settlement type="city">Pise</settlement></placeName><orgName type="university">Université de Pise</orgName></affiliation></author><author><name sortKey="Newbold, Kate" sort="Newbold, Kate" uniqKey="Newbold K" first="Kate" last="Newbold">Kate Newbold</name><affiliation wicri:level="3"><nlm:affiliation>Department of Oncology, Royal Marsden Hospital, London, United Kingdom.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Department of Oncology, Royal Marsden Hospital, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author><author><name sortKey="Licitra, Lisa F" sort="Licitra, Lisa F" uniqKey="Licitra L" first="Lisa F" last="Licitra">Lisa F. Licitra</name><affiliation wicri:level="3"><nlm:affiliation>Foundation for Cancer Research and Treatment, National Tumor Institute, Milan, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Foundation for Cancer Research and Treatment, National Tumor Institute, Milan</wicri:regionArea><placeName><settlement type="city">Milan</settlement><region nuts="2">Lombardie</region></placeName></affiliation></author><author><name sortKey="Sherman, Steven I" sort="Sherman, Steven I" uniqKey="Sherman S" first="Steven I" last="Sherman">Steven I. Sherman</name><affiliation wicri:level="2"><nlm:affiliation>Department of Endocrine Neoplasia and Hormonal Disorders, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Texas</region></placeName><wicri:cityArea>Department of Endocrine Neoplasia and Hormonal Disorders, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston</wicri:cityArea></affiliation></author><author><name sortKey="Ball, Douglas W" sort="Ball, Douglas W" uniqKey="Ball D" first="Douglas W" last="Ball">Douglas W. Ball</name><affiliation wicri:level="2"><nlm:affiliation>The Johns Hopkins University School of Medicine, Baltimore, Maryland.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Maryland</region></placeName><wicri:cityArea>The Johns Hopkins University School of Medicine, Baltimore</wicri:cityArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2015">2015</date><idno type="RBID">pubmed:25913680</idno><idno type="pmid">25913680</idno><idno type="doi">10.1002/cncr.29395</idno><idno type="wicri:Area/PubMed/Corpus">002A75</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002A75</idno><idno type="wicri:Area/PubMed/Curation">002A05</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002A05</idno><idno type="wicri:Area/PubMed/Checkpoint">002A05</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">002A05</idno><idno type="wicri:Area/Ncbi/Merge">002503</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine-refractory, differentiated thyroid cancer: A clinical outcomes and biomarker assessment.</title><author><name sortKey="Cabanillas, Maria E" sort="Cabanillas, Maria E" uniqKey="Cabanillas M" first="Maria E" last="Cabanillas">Maria E. Cabanillas</name><affiliation wicri:level="2"><nlm:affiliation>Department of Endocrine Neoplasia and Hormonal Disorders, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Texas</region></placeName><wicri:cityArea>Department of Endocrine Neoplasia and Hormonal Disorders, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston</wicri:cityArea></affiliation></author><author><name sortKey="Schlumberger, Martin" sort="Schlumberger, Martin" uniqKey="Schlumberger M" first="Martin" last="Schlumberger">Martin Schlumberger</name><affiliation wicri:level="4"><nlm:affiliation>Department of Nuclear Medicine and Endocrine Oncology, Gustave Roussy Institute and Université Paris-Sud, Villejuif, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Nuclear Medicine and Endocrine Oncology, Gustave Roussy Institute and Université Paris-Sud, Villejuif</wicri:regionArea><wicri:noRegion>Villejuif</wicri:noRegion><orgName type="university">Université Paris-Sud</orgName><placeName><settlement type="city">Orsay</settlement><region type="region" nuts="2">Île-de-France</region></placeName></affiliation></author><author><name sortKey="Jarzab, Barbara" sort="Jarzab, Barbara" uniqKey="Jarzab B" first="Barbara" last="Jarzab">Barbara Jarzab</name><affiliation wicri:level="1"><nlm:affiliation>Department of Nuclear Medicine and Endocrine Oncology, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice Branch, Gliwice Poland, Wybrzeze Armii Krajowej 15, 44-101 Gliwice, Poland.</nlm:affiliation><country xml:lang="fr">Pologne</country><wicri:regionArea>Department of Nuclear Medicine and Endocrine Oncology, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice Branch, Gliwice Poland, Wybrzeze Armii Krajowej 15, 44-101 Gliwice</wicri:regionArea><wicri:noRegion>44-101 Gliwice</wicri:noRegion></affiliation></author><author><name sortKey="Martins, Renato G" sort="Martins, Renato G" uniqKey="Martins R" first="Renato G" last="Martins">Renato G. Martins</name><affiliation wicri:level="2"><nlm:affiliation>Department of Thoracic/Head and Neck Oncology, School of Medicine, University of Washington, Seattle, Washington.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Washington (État)</region></placeName><wicri:cityArea>Department of Thoracic/Head and Neck Oncology, School of Medicine, University of Washington, Seattle</wicri:cityArea></affiliation></author><author><name sortKey="Pacini, Furio" sort="Pacini, Furio" uniqKey="Pacini F" first="Furio" last="Pacini">Furio Pacini</name><affiliation wicri:level="1"><nlm:affiliation>Section of Endocrinology, University of Siena, Siena, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Section of Endocrinology, University of Siena, Siena</wicri:regionArea><wicri:noRegion>Siena</wicri:noRegion></affiliation></author><author><name sortKey="Robinson, Bruce" sort="Robinson, Bruce" uniqKey="Robinson B" first="Bruce" last="Robinson">Bruce Robinson</name><affiliation wicri:level="4"><nlm:affiliation>Faculty of Medicine, Cancer Genetics Unit, Kolling Institute, Royal North Shore Hospital, University of Sydney, New South Wales, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Faculty of Medicine, Cancer Genetics Unit, Kolling Institute, Royal North Shore Hospital, University of Sydney, New South Wales</wicri:regionArea><orgName type="university">Université de Sydney</orgName><placeName><settlement type="city">Sydney</settlement><region type="état">Nouvelle-Galles du Sud</region></placeName></affiliation></author><author><name sortKey="Mccaffrey, Judith C" sort="Mccaffrey, Judith C" uniqKey="Mccaffrey J" first="Judith C" last="Mccaffrey">Judith C. Mccaffrey</name><affiliation wicri:level="2"><nlm:affiliation>H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Floride</region></placeName><wicri:cityArea>H. Lee Moffitt Cancer Center and Research Institute, Tampa</wicri:cityArea></affiliation></author><author><name sortKey="Shah, Manisha H" sort="Shah, Manisha H" uniqKey="Shah M" first="Manisha H" last="Shah">Manisha H. Shah</name><affiliation wicri:level="2"><nlm:affiliation>Ohio State University Comprehensive Cancer Center, Columbus, Ohio.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Ohio</region></placeName><wicri:cityArea>Ohio State University Comprehensive Cancer Center, Columbus</wicri:cityArea></affiliation></author><author><name sortKey="Bodenner, Donald L" sort="Bodenner, Donald L" uniqKey="Bodenner D" first="Donald L" last="Bodenner">Donald L. Bodenner</name><affiliation wicri:level="2"><nlm:affiliation>Department of Geriatrics, University of Arkansas for Medical sciences, Little Rock, Arkansas.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Arkansas</region></placeName><wicri:cityArea>Department of Geriatrics, University of Arkansas for Medical sciences, Little Rock</wicri:cityArea></affiliation></author><author><name sortKey="Topliss, Duncan" sort="Topliss, Duncan" uniqKey="Topliss D" first="Duncan" last="Topliss">Duncan Topliss</name><affiliation wicri:level="1"><nlm:affiliation>Department of Endocrinology and Diabetes, The Alfred Hospital, Melbourne, Victoria, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Department of Endocrinology and Diabetes, The Alfred Hospital, Melbourne, Victoria</wicri:regionArea><wicri:noRegion>Victoria</wicri:noRegion></affiliation></author><author><name sortKey="Andresen, Corina" sort="Andresen, Corina" uniqKey="Andresen C" first="Corina" last="Andresen">Corina Andresen</name><affiliation wicri:level="2"><nlm:affiliation>Eisai Inc, Woodcliff Lake, New Jersey.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">New Jersey</region></placeName><wicri:cityArea>Eisai Inc, Woodcliff Lake</wicri:cityArea></affiliation></author><author><name sortKey="O Brien, James P" sort="O Brien, James P" uniqKey="O Brien J" first="James P" last="O'Brien">James P. O'Brien</name><affiliation wicri:level="2"><nlm:affiliation>Eisai Inc, Woodcliff Lake, New Jersey.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">New Jersey</region></placeName><wicri:cityArea>Eisai Inc, Woodcliff Lake</wicri:cityArea></affiliation></author><author><name sortKey="Ren, Min" sort="Ren, Min" uniqKey="Ren M" first="Min" last="Ren">Min Ren</name><affiliation wicri:level="2"><nlm:affiliation>Eisai Inc, Woodcliff Lake, New Jersey.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">New Jersey</region></placeName><wicri:cityArea>Eisai Inc, Woodcliff Lake</wicri:cityArea></affiliation></author><author><name sortKey="Funahashi, Yasuhiro" sort="Funahashi, Yasuhiro" uniqKey="Funahashi Y" first="Yasuhiro" last="Funahashi">Yasuhiro Funahashi</name><affiliation wicri:level="2"><nlm:affiliation>Eisai Inc, Andover, Massachusetts.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Massachusetts</region></placeName><wicri:cityArea>Eisai Inc, Andover</wicri:cityArea></affiliation></author><author><name sortKey="Allison, Roger" sort="Allison, Roger" uniqKey="Allison R" first="Roger" last="Allison">Roger Allison</name><affiliation wicri:level="1"><nlm:affiliation>Cancer Care Services, The Royal Brisbane and Women's Hospital, Herston, Queensland, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Cancer Care Services, The Royal Brisbane and Women's Hospital, Herston, Queensland</wicri:regionArea><wicri:noRegion>Queensland</wicri:noRegion></affiliation></author><author><name sortKey="Elisei, Rossella" sort="Elisei, Rossella" uniqKey="Elisei R" first="Rossella" last="Elisei">Rossella Elisei</name><affiliation wicri:level="4"><nlm:affiliation>Department of Endocrinology, University of Pisa, Pisa, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Endocrinology, University of Pisa, Pisa</wicri:regionArea><placeName><settlement type="city">Pise</settlement><region nuts="2">Toscane</region><settlement type="city">Pise</settlement></placeName><orgName type="university">Université de Pise</orgName></affiliation></author><author><name sortKey="Newbold, Kate" sort="Newbold, Kate" uniqKey="Newbold K" first="Kate" last="Newbold">Kate Newbold</name><affiliation wicri:level="3"><nlm:affiliation>Department of Oncology, Royal Marsden Hospital, London, United Kingdom.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Department of Oncology, Royal Marsden Hospital, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author><author><name sortKey="Licitra, Lisa F" sort="Licitra, Lisa F" uniqKey="Licitra L" first="Lisa F" last="Licitra">Lisa F. Licitra</name><affiliation wicri:level="3"><nlm:affiliation>Foundation for Cancer Research and Treatment, National Tumor Institute, Milan, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Foundation for Cancer Research and Treatment, National Tumor Institute, Milan</wicri:regionArea><placeName><settlement type="city">Milan</settlement><region nuts="2">Lombardie</region></placeName></affiliation></author><author><name sortKey="Sherman, Steven I" sort="Sherman, Steven I" uniqKey="Sherman S" first="Steven I" last="Sherman">Steven I. Sherman</name><affiliation wicri:level="2"><nlm:affiliation>Department of Endocrine Neoplasia and Hormonal Disorders, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Texas</region></placeName><wicri:cityArea>Department of Endocrine Neoplasia and Hormonal Disorders, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston</wicri:cityArea></affiliation></author><author><name sortKey="Ball, Douglas W" sort="Ball, Douglas W" uniqKey="Ball D" first="Douglas W" last="Ball">Douglas W. Ball</name><affiliation wicri:level="2"><nlm:affiliation>The Johns Hopkins University School of Medicine, Baltimore, Maryland.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Maryland</region></placeName><wicri:cityArea>The Johns Hopkins University School of Medicine, Baltimore</wicri:cityArea></affiliation></author></analytic><series><title level="j">Cancer</title><idno type="eISSN">1097-0142</idno><imprint><date when="2015" type="published">2015</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Aged</term><term>Antineoplastic Agents (therapeutic use)</term><term>Biomarkers, Tumor (analysis)</term><term>Disease Progression</term><term>Female</term><term>Humans</term><term>Iodine Radioisotopes (adverse effects)</term><term>Iodine Radioisotopes (therapeutic use)</term><term>Male</term><term>Middle Aged</term><term>Phenylurea Compounds (adverse effects)</term><term>Phenylurea Compounds (therapeutic use)</term><term>Protein Kinase Inhibitors (adverse effects)</term><term>Protein Kinase Inhibitors (therapeutic use)</term><term>Quinolines (adverse effects)</term><term>Quinolines (therapeutic use)</term><term>Thyroid Neoplasms (drug therapy)</term><term>Thyroid Neoplasms (mortality)</term><term>Treatment Outcome</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Antinéoplasiques (usage thérapeutique)</term><term>Femelle</term><term>Humains</term><term>Inhibiteurs de protéines kinases (effets indésirables)</term><term>Inhibiteurs de protéines kinases (usage thérapeutique)</term><term>Marqueurs biologiques tumoraux (analyse)</term><term>Mâle</term><term>Phénylurées (effets indésirables)</term><term>Phénylurées (usage thérapeutique)</term><term>Quinoléines (effets indésirables)</term><term>Quinoléines (usage thérapeutique)</term><term>Radio-isotopes de l'iode (effets indésirables)</term><term>Radio-isotopes de l'iode (usage thérapeutique)</term><term>Résultat thérapeutique</term><term>Sujet âgé</term><term>Tumeurs de la thyroïde (mortalité)</term><term>Tumeurs de la thyroïde (traitement médicamenteux)</term><term>Évolution de la maladie</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Iodine Radioisotopes</term><term>Phenylurea Compounds</term><term>Protein Kinase Inhibitors</term><term>Quinolines</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analysis" xml:lang="en"><term>Biomarkers, Tumor</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antineoplastic Agents</term><term>Iodine Radioisotopes</term><term>Phenylurea Compounds</term><term>Protein Kinase Inhibitors</term><term>Quinolines</term></keywords><keywords scheme="MESH" qualifier="analyse" xml:lang="fr"><term>Marqueurs biologiques tumoraux</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Thyroid Neoplasms</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Inhibiteurs de protéines kinases</term><term>Phénylurées</term><term>Quinoléines</term><term>Radio-isotopes de l'iode</term></keywords><keywords scheme="MESH" qualifier="mortality" xml:lang="en"><term>Thyroid Neoplasms</term></keywords><keywords scheme="MESH" qualifier="mortalité" xml:lang="fr"><term>Tumeurs de la thyroïde</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Tumeurs de la thyroïde</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antinéoplasiques</term><term>Inhibiteurs de protéines kinases</term><term>Phénylurées</term><term>Quinoléines</term><term>Radio-isotopes de l'iode</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Disease Progression</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Treatment Outcome</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Femelle</term><term>Humains</term><term>Mâle</term><term>Résultat thérapeutique</term><term>Sujet âgé</term><term>Évolution de la maladie</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Lenvatinib is an oral, multitargeted tyrosine kinase inhibitor of the vascular endothelial growth factor receptors 1 through 3 (VEGFR1-VEGFR3), fibroblast growth factor receptors 1 through 4 (FGFR1-FGFR4), platelet-derived growth factor receptor α (PDGFRα), ret proto-oncogene (RET), and v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog (KIT) signaling networks implicated in tumor angiogenesis. Positive phase 1 results in solid tumors prompted a phase 2 trial in patients with advanced, radioiodine-refractory, differentiated thyroid cancer (RR-DTC).</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">25913680</PMID><DateCreated><Year>2015</Year><Month>08</Month><Day>07</Day></DateCreated><DateCompleted><Year>2015</Year><Month>10</Month><Day>27</Day></DateCompleted><DateRevised><Year>2017</Year><Month>02</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-0142</ISSN><JournalIssue CitedMedium="Internet"><Volume>121</Volume><Issue>16</Issue><PubDate><Year>2015</Year><Month>Aug</Month><Day>15</Day></PubDate></JournalIssue><Title>Cancer</Title><ISOAbbreviation>Cancer</ISOAbbreviation></Journal><ArticleTitle>A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine-refractory, differentiated thyroid cancer: A clinical outcomes and biomarker assessment.</ArticleTitle><Pagination><MedlinePgn>2749-56</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/cncr.29395</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Lenvatinib is an oral, multitargeted tyrosine kinase inhibitor of the vascular endothelial growth factor receptors 1 through 3 (VEGFR1-VEGFR3), fibroblast growth factor receptors 1 through 4 (FGFR1-FGFR4), platelet-derived growth factor receptor α (PDGFRα), ret proto-oncogene (RET), and v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog (KIT) signaling networks implicated in tumor angiogenesis. Positive phase 1 results in solid tumors prompted a phase 2 trial in patients with advanced, radioiodine-refractory, differentiated thyroid cancer (RR-DTC).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Fifty-eight patients with RR-DTC who had disease progression during the previous 12 months received lenvatinib 24 mg once daily in 28-day cycles until disease progression, unmanageable toxicity, withdrawal, or death. Previous VEGFR-targeted therapy was permitted. The primary endpoint was the objective response rate (ORR) based on independent imaging review. Secondary endpoints included progression-free survival (PFS) and safety. Serum levels of 51 circulating cytokines and angiogenic factors also were assessed.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">After ≥14 months of follow-up, patients had an ORR of 50% (95% confidence interval [CI], 37%-63%) with only partial responses reported. The median time to response was 3.6 months, the median response duration was 12.7 months, and the median PFS was 12.6 months (95% CI, 9.9-16.1 months). The ORR for patients who had received previous VEGF therapy (n = 17) was 59% (95% CI, 33%-82%). Lower baseline levels of angiopoietin-2 were suggestive of tumor response and longer PFS. Grade 3 and 4 treatment-emergent adverse events, regardless of their relation to treatment, occurred in 72% of patients and most frequently included weight loss (12%), hypertension (10%), proteinuria (10%), and diarrhea (10%).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">In patients with and without prior exposure to VEGF therapy, the encouraging response rates, median time to response, and PFS for lenvatinib have prompted further investigation in a phase 3 trial. Cancer 2015;121:2749-2756. © 2015 American Cancer Society.</AbstractText><CopyrightInformation>© 2015 The Authors. Cancer published by Wiley Periodicals, Inc. on behalf of American Cancer Society.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cabanillas</LastName><ForeName>Maria E</ForeName><Initials>ME</Initials><AffiliationInfo><Affiliation>Department of Endocrine Neoplasia and Hormonal Disorders, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schlumberger</LastName><ForeName>Martin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Nuclear Medicine and Endocrine Oncology, Gustave Roussy Institute and Université Paris-Sud, Villejuif, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jarzab</LastName><ForeName>Barbara</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Nuclear Medicine and Endocrine Oncology, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice Branch, Gliwice Poland, Wybrzeze Armii Krajowej 15, 44-101 Gliwice, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martins</LastName><ForeName>Renato G</ForeName><Initials>RG</Initials><AffiliationInfo><Affiliation>Department of Thoracic/Head and Neck Oncology, School of Medicine, University of Washington, Seattle, Washington.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pacini</LastName><ForeName>Furio</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Section of Endocrinology, University of Siena, Siena, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Robinson</LastName><ForeName>Bruce</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, Cancer Genetics Unit, Kolling Institute, Royal North Shore Hospital, University of Sydney, New South Wales, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McCaffrey</LastName><ForeName>Judith C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shah</LastName><ForeName>Manisha H</ForeName><Initials>MH</Initials><AffiliationInfo><Affiliation>Ohio State University Comprehensive Cancer Center, Columbus, Ohio.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bodenner</LastName><ForeName>Donald L</ForeName><Initials>DL</Initials><AffiliationInfo><Affiliation>Department of Geriatrics, University of Arkansas for Medical sciences, Little Rock, Arkansas.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Topliss</LastName><ForeName>Duncan</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Endocrinology and Diabetes, The Alfred Hospital, Melbourne, Victoria, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Andresen</LastName><ForeName>Corina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Eisai Inc, Woodcliff Lake, New Jersey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>O'Brien</LastName><ForeName>James P</ForeName><Initials>JP</Initials><AffiliationInfo><Affiliation>Eisai Inc, Woodcliff Lake, New Jersey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ren</LastName><ForeName>Min</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Eisai Inc, Woodcliff Lake, New Jersey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Funahashi</LastName><ForeName>Yasuhiro</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Eisai Inc, Andover, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Allison</LastName><ForeName>Roger</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Cancer Care Services, The Royal Brisbane and Women's Hospital, Herston, Queensland, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Elisei</LastName><ForeName>Rossella</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Endocrinology, University of Pisa, Pisa, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Newbold</LastName><ForeName>Kate</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Oncology, Royal Marsden Hospital, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Licitra</LastName><ForeName>Lisa F</ForeName><Initials>LF</Initials><AffiliationInfo><Affiliation>Foundation for Cancer Research and Treatment, National Tumor Institute, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sherman</LastName><ForeName>Steven I</ForeName><Initials>SI</Initials><AffiliationInfo><Affiliation>Department of Endocrine Neoplasia and Hormonal Disorders, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ball</LastName><ForeName>Douglas W</ForeName><Initials>DW</Initials><AffiliationInfo><Affiliation>The Johns Hopkins University School of Medicine, Baltimore, Maryland.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 CA016672</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D017427">Clinical Trial, Phase II</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>04</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cancer</MedlineTA><NlmUniqueID>0374236</NlmUniqueID><ISSNLinking>0008-543X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014408">Biomarkers, Tumor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007457">Iodine Radioisotopes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010671">Phenylurea Compounds</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D047428">Protein Kinase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011804">Quinolines</NameOfSubstance></Chemical><Chemical><RegistryNumber>EE083865G2</RegistryNumber><NameOfSubstance UI="C531958">lenvatinib</NameOfSubstance></Chemical></ChemicalList><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>Lancet Oncol. 2002 Jul;3(7):407-14</RefSource><PMID Version="1">12142170</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cancer Res. 2013 Mar 15;73(6):1649-57</RefSource><PMID Version="1">23467610</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Endocrinol Metab. 2010 Nov;95(11):5018-27</RefSource><PMID Version="1">20739388</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nat Rev Endocrinol. 2011 Oct;7(10):617-24</RefSource><PMID Version="1">21862995</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2015 Feb 12;372(7):621-30</RefSource><PMID Version="1">25671254</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2009 Apr 1;27(10):1675-84</RefSource><PMID Version="1">19255327</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Endocr Relat Cancer. 2005 Jun;12(2):273-80</RefSource><PMID Version="1">15947102</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Cancer Res. 2010 Nov 1;16(21):5260-8</RefSource><PMID Version="1">20847059</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Natl Cancer Inst. 2000 Feb 2;92(3):205-16</RefSource><PMID Version="1">10655437</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Oncol (R Coll Radiol). 2010 Aug;22(6):464-8</RefSource><PMID Version="1">20452757</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2008 Oct 10;26(29):4708-13</RefSource><PMID Version="1">18541897</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Int J Cancer. 2008 Feb 1;122(3):664-71</RefSource><PMID Version="1">17943726</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Endocrinol Metab. 2012 Jun;97(6):E878-87</RefSource><PMID Version="1">22496497</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann Oncol. 2012 Oct;23 Suppl 7:vii110-9</RefSource><PMID Version="1">22997443</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Thyroid Res. 2012;2012:618985</RefSource><PMID Version="1">22530159</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet Oncol. 2010 Oct;11(10):962-72</RefSource><PMID Version="1">20851682</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mod Pathol. 2011 Apr;24 Suppl 2:S44-52</RefSource><PMID Version="1">21455200</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Endocrinol Metab. 2006 Aug;91(8):2892-9</RefSource><PMID Version="1">16684830</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Cancer Res. 2011 Apr 1;17(7):2044-54</RefSource><PMID Version="1">21325074</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet Oncol. 2012 Sep;13(9):897-905</RefSource><PMID Version="1">22898678</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Br J Cancer. 2012 May 8;106(10):1598-604</RefSource><PMID Version="1">22516948</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nat Rev Cancer. 2010 Aug;10(8):575-85</RefSource><PMID Version="1">20651738</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet Oncol. 2009 Oct;10(10):992-1000</RefSource><PMID Version="1">19796751</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cancer Lett. 2013 Oct 28;340(1):97-103</RefSource><PMID Version="1">23856031</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Cancer Res. 2008 Sep 1;14(17):5459-65</RefSource><PMID Version="1">18765537</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Endocrinol Metab. 2001 Feb;86(2):656-8</RefSource><PMID Version="1">11158026</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2008 Jul 3;359(1):31-42</RefSource><PMID Version="1">18596272</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Eur J Endocrinol. 2012 Jan;166(1):5-11</RefSource><PMID Version="1">21890651</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nature. 2005 Dec 15;438(7070):967-74</RefSource><PMID Version="1">16355214</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2010 May 1;28(13):2280-5</RefSource><PMID Version="1">20351323</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014408" MajorTopicYN="N">Biomarkers, Tumor</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007457" MajorTopicYN="N">Iodine Radioisotopes</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010671" MajorTopicYN="N">Phenylurea Compounds</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D047428" MajorTopicYN="N">Protein Kinase Inhibitors</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011804" MajorTopicYN="N">Quinolines</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013964" MajorTopicYN="N">Thyroid Neoplasms</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><OtherID Source="NLM">NIHMS768057</OtherID><OtherID Source="NLM">PMC4803478</OtherID><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">biomarkers</Keyword><Keyword MajorTopicYN="N">differentiated thyroid cancer</Keyword><Keyword MajorTopicYN="N">lenvatinib</Keyword><Keyword MajorTopicYN="N">multikinase inhibitor</Keyword><Keyword MajorTopicYN="N">phase 2</Keyword><Keyword MajorTopicYN="N">radioiodine refractory</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>11</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2015</Year><Month>03</Month><Day>03</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>03</Month><Day>05</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>4</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>4</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>10</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25913680</ArticleId><ArticleId IdType="doi">10.1002/cncr.29395</ArticleId><ArticleId IdType="pmc">PMC4803478</ArticleId><ArticleId IdType="mid">NIHMS768057</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Australie</li><li>France</li><li>Italie</li><li>Pologne</li><li>Royaume-Uni</li><li>États-Unis</li></country><region><li>Angleterre</li><li>Arkansas</li><li>Floride</li><li>Grand Londres</li><li>Lombardie</li><li>Maryland</li><li>Massachusetts</li><li>New Jersey</li><li>Nouvelle-Galles du Sud</li><li>Ohio</li><li>Texas</li><li>Toscane</li><li>Washington (État)</li><li>Île-de-France</li></region><settlement><li>Londres</li><li>Milan</li><li>Orsay</li><li>Pise</li><li>Sydney</li></settlement><orgName><li>Université Paris-Sud</li><li>Université de Pise</li><li>Université de Sydney</li></orgName></list><tree><country name="États-Unis"><region name="Texas"><name sortKey="Cabanillas, Maria E" sort="Cabanillas, Maria E" uniqKey="Cabanillas M" first="Maria E" last="Cabanillas">Maria E. Cabanillas</name></region><name sortKey="Andresen, Corina" sort="Andresen, Corina" uniqKey="Andresen C" first="Corina" last="Andresen">Corina Andresen</name><name sortKey="Ball, Douglas W" sort="Ball, Douglas W" uniqKey="Ball D" first="Douglas W" last="Ball">Douglas W. Ball</name><name sortKey="Bodenner, Donald L" sort="Bodenner, Donald L" uniqKey="Bodenner D" first="Donald L" last="Bodenner">Donald L. Bodenner</name><name sortKey="Funahashi, Yasuhiro" sort="Funahashi, Yasuhiro" uniqKey="Funahashi Y" first="Yasuhiro" last="Funahashi">Yasuhiro Funahashi</name><name sortKey="Martins, Renato G" sort="Martins, Renato G" uniqKey="Martins R" first="Renato G" last="Martins">Renato G. Martins</name><name sortKey="Mccaffrey, Judith C" sort="Mccaffrey, Judith C" uniqKey="Mccaffrey J" first="Judith C" last="Mccaffrey">Judith C. Mccaffrey</name><name sortKey="O Brien, James P" sort="O Brien, James P" uniqKey="O Brien J" first="James P" last="O'Brien">James P. O'Brien</name><name sortKey="Ren, Min" sort="Ren, Min" uniqKey="Ren M" first="Min" last="Ren">Min Ren</name><name sortKey="Shah, Manisha H" sort="Shah, Manisha H" uniqKey="Shah M" first="Manisha H" last="Shah">Manisha H. Shah</name><name sortKey="Sherman, Steven I" sort="Sherman, Steven I" uniqKey="Sherman S" first="Steven I" last="Sherman">Steven I. Sherman</name></country><country name="France"><region name="Île-de-France"><name sortKey="Schlumberger, Martin" sort="Schlumberger, Martin" uniqKey="Schlumberger M" first="Martin" last="Schlumberger">Martin Schlumberger</name></region></country><country name="Pologne"><noRegion><name sortKey="Jarzab, Barbara" sort="Jarzab, Barbara" uniqKey="Jarzab B" first="Barbara" last="Jarzab">Barbara Jarzab</name></noRegion></country><country name="Italie"><noRegion><name sortKey="Pacini, Furio" sort="Pacini, Furio" uniqKey="Pacini F" first="Furio" last="Pacini">Furio Pacini</name></noRegion><name sortKey="Elisei, Rossella" sort="Elisei, Rossella" uniqKey="Elisei R" first="Rossella" last="Elisei">Rossella Elisei</name><name sortKey="Licitra, Lisa F" sort="Licitra, Lisa F" uniqKey="Licitra L" first="Lisa F" last="Licitra">Lisa F. Licitra</name></country><country name="Australie"><region name="Nouvelle-Galles du Sud"><name sortKey="Robinson, Bruce" sort="Robinson, Bruce" uniqKey="Robinson B" first="Bruce" last="Robinson">Bruce Robinson</name></region><name sortKey="Allison, Roger" sort="Allison, Roger" uniqKey="Allison R" first="Roger" last="Allison">Roger Allison</name><name sortKey="Topliss, Duncan" sort="Topliss, Duncan" uniqKey="Topliss D" first="Duncan" last="Topliss">Duncan Topliss</name></country><country name="Royaume-Uni"><region name="Angleterre"><name sortKey="Newbold, Kate" sort="Newbold, Kate" uniqKey="Newbold K" first="Kate" last="Newbold">Kate Newbold</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002503 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 002503 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Ncbi
|étape= Merge
|type= RBID
|clé= pubmed:25913680
|texte= A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine-refractory, differentiated thyroid cancer: A clinical outcomes and biomarker assessment.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:25913680" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |